0N5A Stock Chart & Stats
€1.54
€0.07(4.58%)
At close: 4:00 PM EST
€1.54
€0.07(4.58%)
Day’s Range― - ―
52-Week Range€1.35 - €2.58
Previous CloseN/A
Volume9.00
Average Volume (3M)4.00
Market Cap
€25.75M
Enterprise Value€28.81
Total Cash (Recent Filing)€286.00K
Total Debt (Recent Filing)€3.97M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 18, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding14,716,976
10 Day Avg. Volume7
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.27
Price to Sales (P/S)1.58
P/FCF Ratio-9.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsAn approximately 82% gross margin indicates strong product-level economics in the implant business. This provides meaningful room to support selling, regulatory, and development costs, and could help the company benefit disproportionately if revenue stabilizes or operating efficiency improves.
Manageable LeverageLow leverage and positive equity provide a financial cushion relative to a heavily debt-funded structure. This reduces immediate balance-sheet pressure, preserves flexibility for operating needs, and limits the extent to which interest obligations compound the company’s profitability challenges.
Focused Orthopedic Medtech PlatformA focused portfolio spanning fracture-fixation implants and the instruments used to place them creates a coherent commercial platform. Combining products used within the same surgical workflow can support surgeon familiarity, hospital adoption, and deeper relationships across the orthopedic care pathway.
Bears Say
Persistent UnprofitabilityPersistent net losses show that strong gross profitability has not yet translated into a viable earnings model. Continued operating losses can erode equity over time, restrict internal investment capacity, and make a durable recovery dependent on substantial cost improvement or stronger revenue scale.
Ongoing Cash BurnNegative operating cash flow across every provided period indicates that the core business is not self-funding. Continued cash consumption can require external financing or tighter investment decisions, reducing resilience and limiting the company’s ability to fund product development and commercial expansion independently.
Weakening Revenue MomentumThe roughly 10% TTM revenue decline interrupts the company’s previously stable €11–13M revenue range and weakens operating leverage. Lower scale makes it harder to absorb fixed costs, sustain development spending, and convert the high gross margin into positive operating and net earnings.
0N5A FAQ
What was aap Implantate AG’s price range in the past 12 months?
aap Implantate AG lowest share price was €1.35 and its highest was €2.58 in the past 12 months.
What is aap Implantate AG’s market cap?
aap Implantate AG’s market cap is €25.75M.
When is aap Implantate AG’s upcoming earnings report date?
aap Implantate AG’s upcoming earnings report date is Aug 18, 2027 which is in 342 days.
How were aap Implantate AG’s earnings last quarter?
aap Implantate AG released its earnings results on Aug 17, 2026. The company reported -€0.078 earnings per share for the quarter.
Is aap Implantate AG overvalued?
According to Wall Street analysts aap Implantate AG’s price is currently Overvalued.
Does aap Implantate AG pay dividends?
aap Implantate AG does not currently pay dividends.
What is aap Implantate AG’s EPS estimate?
aap Implantate AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aap Implantate AG have?
aap Implantate AG has 14,716,976 shares outstanding.
What happened to aap Implantate AG’s price movement after its last earnings report?
aap Implantate AG reported an EPS of -€0.078 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of aap Implantate AG?
Currently, no hedge funds are holding shares in GB:0N5A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aap Implantate Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
aap Implantate AG
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Eckert & Ziegler Strahlen und Medizintechnik
―
Geratherm Medical
―
MagForce AG
―
elexxion AG
―